[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-367776-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-367776-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","linc00162-silencing-enhances-sorafenib-sensitivity-and-inhibits-thyroid-cancer-cells-progression-through-modulation-of-mapk-signaling-and-apoptosis","LINC00162 silencing enhances sorafenib sensitivity and inhibits thyroid cancer cells progression through modulation of MAPK signaling and apoptosis","","LINC00162 lncRNA silencing was assessed for its ability to modulate thyroid cancer chemosensitivity to sorafenib. Experiments compared LINC00162 siRNA-transfected cells, sorafenib-treated cells, combined siRNA plus sorafenib treatment, and a control group. MTT, flow cytometry, gene expression, and migration and colony-formation assays showed that silencing reduced B-CPAP viability and IC50. Combination treatment markedly increased apoptosis, caused Sub-G1 and G2-M arrest, altered BAX/CASP/BCL2 and MYC/Cyclin D/TP53, inhibited migration, and suppressed MAPK, KRAS, and RAF signaling.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/linc00162-silencing-enhances-sorafenib-sensitivity-and-inhibits-thyroid-cancer-cells-progression-through-modulation-of-mapk-signaling-and-apoptosis/367776/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/linc00162-silencing-enhances-sorafenib-sensitivity-and-inhibits-thyroid-cancer-cells-progression-through-modulation-of-mapk-signaling-and-apoptosis/367776.png","ImageObject",300,407,{"name":42,"@type":43},"McGucket","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How does LINC00162 silencing affect thyroid cancer cells?","Question",{"text":63,"@type":64},"LINC00162 siRNA silencing reduces the viability of B-CPAP thyroid cancer cells and increases sensitivity to sorafenib. It also induces apoptosis and Sub-G1 cell-cycle arrest.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What is the impact of combining LINC00162 siRNA with sorafenib?",{"text":68,"@type":64},"The combination significantly increases the apoptosis rate and further arrests cells in Sub-G1 and G2-M phases. It also enhances pro-apoptotic and tumor-suppressive gene expression while reducing anti-apoptotic and cell-cycle genes.",{"name":70,"@type":61,"acceptedAnswer":71},"Which molecular pathways are implicated in the observed drug response?",{"text":72,"@type":64},"The study reports that combination treatment suppresses MAPK pathway gene expression, including MAPK, KRAS, and RAF. This pathway modulation is linked to reduced progression and viability of thyroid cancer cells.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},367776,1790196852,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":118,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":104,"preview_page_count":33,"preview_urls":144},1236954412713,"https://us-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nLINC00162 silencing enhances sorafenib sensitivity and inhibits thyroid cancer cells progression through modulation of MAPK signaling and apoptosis  \nMaryam Hejazi1, Seyedeh Zahra Bahojb Mahdavi2, Saba Abedimanesh2, Ramin Heshmat1, Bagher Larijani3, Amir Ali Mokhtarzadeh2􀀍, Gita Shafiee1􀀍 &  \nSeyed Mohammad Tavangar1,4􀀍  \nMany studies have reported the aberrant expression of lncRNAs and indicated their role in cancer progression and drug resistance across various cancers. In this study, we aimed to evaluate the effect of LINC00162 lncRNA on the chemosensitivity of thyroid cancer cells, both individually and in combination with sorafenib, on various biological processes. In this regard, we conducted our experiments in several groups: (1) LINC00162 siRNA-transfected cells,(2) Sorafenib-treated cells,(3) Cells that received both siRNA transfection and sorafenib treatment (4) Control group. MTT assay results revealed that siRNA-mediated silencing of LINC00162 reduced the viability of the B-CPAP thyroid cancer cells and increased the sensitivity of these cells to sorafenib by reducing its IC50 . Flow cytometry analysis of apoptosis and cell cycle progression indicated that LINC00162 silencing induced apoptosis and Sub-G1 cell cycle arrest, while its combination with sorafenib significantly increased the apoptosis rate and also arrested cells in the G2-M phase in addition to the Sub-G1 phase. This combination treatment increased the expression of apoptosis-related genes BAX, CASP3, CASP9 while decreasing BCL2 expression. Additionally, significant inhibition of the cell-cycle related genes MYC and Cyclin D and upregulation ofTP53 were observed following combination treatment. Furthermore, the combination therapy reduced the migration of B-CPAP cells through the downregulation of MMP-3 and MMP-9. Colony sizes and numbers also decreased following siRNA-mediated silencing of LINC00162 and sorafenib treatment. qRT-PCR analysis of stemness-related genes, including NANOG, SOX2, CD44, and CD133 confirmed the findings ofthe colony formation assay. To understand the underlying mechanisms of LINC00162 lncRNA in thyroid cancer progression, we evaluated the expression of MAPK pathway genes. Our findings indicated that LINC00162 silencing, in combination with sorafenib, reduced the expression of MAPK, KRAS, and RAF genes. From our findings, we can conclude that LINC00162 silencing, both individually and combined with sorafenib, reduced the progression and viability of thyroid cancer cells through modulating genes involved in key pathways and could be considered a new therapeutic approach for the treatment of papillary thyroid cancer (PTC) .  \nKeywords LINC00162, Thyroid Cancer, Sorafenib, Chemosensitivity, MAPK pathway, Apoptosis, Autophagy, LncRNA  \nThyroid cancer, ranked as the 9th most prevalent cancer, accounted for 586,000 cases globally in 20201. The incidence rate of thyroid cancer in affluent and middle-income countries has steadily increased from 1998 to  \n1Chronic Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran. 2Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.  \n3Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran. 4Department of Pathology, Dr. Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran. 􀀍 email: [ahad.mokhtarzadeh@gmail.com](ahad.mokhtarzadeh@gmail.com); [gshafee.endocrine@gmail.com](gshafee.endocrine@gmail.com); [tavangar@ams.ac.ir](tavangar@ams.ac.ir)  \n[www. nature.com/scientificreports/](www. nature.com/scientificreports/)  \n20122. Differentiated thyroid cancer (DTC), a subtype of thyroid cancer, consists of papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC)3. Common tumor treatments, su","cbCairMYUH4cUjtK","https://ap.wps.com/l/cbCairMYUH4cUjtK","pdf",4864029,"English","# Study aim and experimental groups\n# Cell viability and apoptosis effects\n# Cell-cycle arrest and gene expression changes\n# Migration inhibition and colony formation\n# Stemness and MAPK pathway mechanism","[{\"question\":\"How does LINC00162 silencing affect thyroid cancer cells?\",\"answer\":\"LINC00162 siRNA silencing reduces the viability of B-CPAP thyroid cancer cells and increases sensitivity to sorafenib. It also induces apoptosis and Sub-G1 cell-cycle arrest.\"},{\"question\":\"What is the impact of combining LINC00162 siRNA with sorafenib?\",\"answer\":\"The combination significantly increases the apoptosis rate and further arrests cells in Sub-G1 and G2-M phases. It also enhances pro-apoptotic and tumor-suppressive gene expression while reducing anti-apoptotic and cell-cycle genes.\"},{\"question\":\"Which molecular pathways are implicated in the observed drug response?\",\"answer\":\"The study reports that combination treatment suppresses MAPK pathway gene expression, including MAPK, KRAS, and RAF. This pathway modulation is linked to reduced progression and viability of thyroid cancer cells.\"}]","LINC00162 silencing enhances sorafenib sensitivity and inhibits thyroid cancer cells progression through modulation of MAPK signaling and apoptosis | PDF",1790172550,[145,149,153,157],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f28adb4e008036447fa0b61bebef521f.webp",983,1291,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c48da1aee223f6dbaa562697e572d25a.webp",982,1290,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8f7be19e3ec4bdec00904adeaae67dbc.webp",981,1289,{"page_no":33,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0acd46688ba92ad23352445bc57c3aec.webp",980,1287]